Orphan Drug Development

Orphan Drug Development
Product Description

Accelerating orphan drug development from candidate selection to commercial manufacture and supply.

With over 300 million people worldwide living with identified rare diseases, the development of new treatments to address these unmet clinical needs is an area of great interest in the pharmaceutical industry.

Despite improvements in regulatory support and commercial rewards for developing orphan drugs, difficulties remain for drug developers in bringing these medicines to market quickly; including limited R&D budgets, alongside an ever-evolving regulatory framework, challenging product development and clinical recruitment.

- Integrated capabilities and expertise- Pre-formulation and API characterisation
- Formulation and process development
- First-in-human clinical testing and acceleration into POC trials
- Bespoke clinical manufacturing and supply (Phase I-III) of drug products into patient trials
- Rapid scale-up and commercial manufacturing of low-volume products

Read more Show less

QUOTIENT SCIENCES LIMITED

  • GB
  • 2017
    On CPHI since
  • 500 - 999
    Employees
Company types
Academic/Research
Consultancy
Contract Service
Manufacturer/Innovator
View company profile
Categories
more categories Show less
Specifications
  • Supplied from
    United Kingdom; United States
More specifications Fewer specifications
Sales Markets
Show more Show less

QUOTIENT SCIENCES LIMITED

  • GB
  • 2017
    On CPHI since
  • 500 - 999
    Employees
Company types
Academic/Research
Consultancy
Contract Service
Manufacturer/Innovator
View company profile

More Products from QUOTIENT SCIENCES LIMITED (16)

  • Clinical Pharmacology

    Product Clinical Pharmacology

    When you are looking for a partner who is dedicated to Phase I trials and early clinical development, rely on Quotient Sciences for the experience and expertise to seamlessly deliver your studies with the highest quality service and speed. We accelerate your molecule from first-in-human to proof-of-concept...
  • Bioanaysis

    Product Bioanaysis

    Delivering rapid bioanalytical data in discovery – preclinical – clinical. Bioanalysis is a critical step in the drug development process.  At Quotient, we are experts in the development, validation, and application of bioanalytical assays.  
    Our dedicated team of bioanalytical chemists...
  • Data Sciences

    Product Data Sciences

    You need data rapidly to make crucial decisions during a study. Faster data means we can provide our customers with earlier interim data and interim PK reports for on-study dosing and formulation decisions.
    We understand on-study changes to early phase study designs and d...
  • Drug Development Consulting

    Product Drug Development Consulting

    Our Drug Development Consultants work with you to design and implement successful drug development programs. With industry leading scientific expertise across a range of technical disciplines, we help customers across all stages of development, from candidate selection to commercial launch.

    Our cons...
  • Global Clinical Trial Supply

    Product Global Clinical Trial Supply

    Accelerate your timeline, with flexible, on-demand delivery. We’ll design and develop your packaging, labelling and distribution strategy for Phase I, Phase II and Phase III clinical studies, so you’ll no longer have to worry about the challenge of getting your drug product to multiple sites in time fo...
  • Pediatric Development

    Product Pediatric Development

    Pediatric formulation and product development

    The development of acceptable, palatable pediatric formulations is a key feature within the industry today, driven by patient needs and regulatory requirements. Quotient Sciences has extensive knowledge and capabilities that enable us to provide you...
  • Inhaled Drug Development

    Product Inhaled Drug Development

    Quotient has a 30 year track record in the development and manufacturing of inhaled drug products. We have experience across a range of drug delivery platforms including dry powder inhalers (DPIs) and solutions/suspensions for inhalation. With integrated capabilities and vast knowledge of nasal and pu...
  • Translational Pharmaceutics - Integrated Programs

    Product Translational Pharmaceutics - Integrated Programs

    Translational Pharmaceutics® accelerates drug development by integrating formulation development, real-time manufacturing and clinical testing. The platform is unique to Quotient Sciences and has been used over the last decade by global pharmaceutical and biotech companies across over 400 drug programs. qq...
  • Oncology

    Product Oncology


    Supporting oncology drug development from candidate selection through to commercial manufacture and supply
    In the past 5 years alone, Quotient has successfully worked on over 300 oncology development projects for 91 different oncology drug candidates spanning 34 different disea...
  • Candidate Selection - Integrated Programs

    Product Candidate Selection - Integrated Programs

    Selecting the right molecules for development - Quickly identify the best drug candidates. Knowing what it takes to develop a successful drug, we help clients select the best molecules for development. Our unique integration of scientific capabilities enables us to provide a complete assessment o...
  • Early Stage Development - Integrated Programs

    Product Early Stage Development - Integrated Programs

    Accelerating molecules through to proof-of-concept - Simplify early development and accelerate to Proof-of Concept.Proof-of-concept (POC) is a key milestone in the development of a new drug candidate. We understand the transition to POC needs to be fast and cost-effective.With fully integrated capabil...
  • Late Stage Development - Integrated Programs

    Product Late Stage Development - Integrated Programs

    .Accelerating products through to commercial manufacture - Speed the journey from proof-of-concept to commercial launch. The journey from proof-of-concept to commercial launch can be complex. Speed is critical but it shouldn’t come at the expense of product quality. Creating patient-centric formulatio...
show all 16 other products

QUOTIENT SCIENCES LIMITED resources (25)

  • CPHI Milan 2024: Excerpts from the Exhibitors

    News CPHI Milan 2024: Excerpts from the Exhibitors

    After another successful year of bringing the pharmaceutical community together at CPHI Milan in October, hear direct from the exhibitors on why the event is so important for them and the industry as a whole. 
    22 Nov 2024
  • Formulation Development at Quotient

    Technical Data Formulation Development at Quotient

    Quotient Sciences has almost 30 years of experience developing a breadth of pharmaceutical formulations across a range of indications. Our innovative approach to formulation development integrates drug product development with clinical evaluation, combined with our experience with over 1,000 molecules at all stages of drug development. 
  • Quotient Sciences acquires UK-based CDMO Arcinova

    News Quotient Sciences acquires UK-based CDMO Arcinova

    With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide
    9 Mar 2021
  • Clinical Pharmacology at Quotient

    Technical Data Clinical Pharmacology at Quotient

    When you are looking for a partner who is dedicated to Phase I trials and early development,rely on Quotient Sciences. 

    We accelerate your molecule from first-in-human to proof-of-concept,helping you make critical decisions earlier. 
    Whatever clinical pharmacology study you require, you can expect a fully integrated program from study design to data reporting.

  • News Quotient Sciences Completes Million Dollar Pharmacy Expansion at Miami Clinic

    Miami, FL/June 22, 2020 - Quotient Sciences, a global pharmaceutical development, clinical and commercial manufacturing organization, announced today the completion of a $1 million dollar pharmacy and laboratory expansion at their Miami, FL clinical pharmacology facility. 


    The expanded pharmacy capabilities offer customers a quick and cost-effective way to start clinical testing, without the need for extensive CMC investment or API consumption at this early stage of development.
    8 Sep 2020
  • Global Formulation & Manufacturing Capabilities

    Technical Data Global Formulation & Manufacturing Capabilities

    With over 30 years’ experience, Quotient Sciences provides full service support for small molecule non-sterile programs, from dosage formulation development through to GMP clinical trial manufacturing and commercial drug product supply.
  • Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm

    News Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm

    Collaboration Expedites Human Clinical Trials for COVID-19 Drug Candidate. A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today [April 28, 2020] by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc. a privately help biotechnology company focused on the development of pharmaceutical products for treatment of infectious diseases.
    4 Sep 2020
  • Clinical Trial Manufacturing at Quotient

    Technical Data Clinical Trial Manufacturing at Quotient

    Understanding that early phase clinical testing is a pivotal milestone in the development of your drug product, Quotient offers a clinical trial manufacturing, testing and certification service designed to meet your individual requirements. 

    Our innovative method of building integrated GMP and GCP programs provides you with a streamlined, flexible approach to drug product supply that reflects your clinical study design and timeline. 


    We understand the time and cost pressures you face during early phase evaluation and work with you to ensure a rapid, seamless path from development to clinical trial supply.

  • News ANA Therapeutics and Quotient Sciences Announce Partnership to Manufacture Niclosamide Drug Candidate as a Potential Treatment for COVID-19 Collaboration

    ANA Therapeutics, a Silicon Valley-based biotech startup, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19.
    19 Aug 2020
  • Commercial Manufacturing at Quotient

    Technical Data Commercial Manufacturing at Quotient

    Pharmaceutical commercial manufacturing - Quotient Sciences is a global player in commercial drug product manufacture of small molecule products for niche therapies including oncology and orphan drugs. 
    Our commercial manufacturing facility located in Philadelphia is designed to handle your high-potency compounds.
  • Pediatric Development at Quotient

    Technical Data Pediatric Development at Quotient

    Pediatric formulation and product development
    The development of acceptable, palatable pediatric formulations is a key feature within the industry today, driven by patient needs and regulatory requirements. 

    Quotient Sciences has extensive knowledge and capabilities that enable us to provide you with a unique integrated pediatric development solution.

  • Taste Masking at Quotient

    Technical Data Taste Masking at Quotient

    Many drug substances are extremely bitter or have other aversive attributes,which can make developing palatable drug products extremely challenging.This is a common problem seen in medicines spanning all therapeutic areas,from antibiotics and painkillers to antihistamines and decongestants. The careful design and development of formulated oral drug products is key to ensuring patient acceptability and compliance for achieving the desired clinical outcomes.
  • 505(b)(2) Product Development at Quotient

    Technical Data 505(b)(2) Product Development at Quotient

    Are you developing a new dosage form for an existing drug? 

    Do you need to explore a different route of administration?

    Quotient has significant experience in 505(b)(2)product development and can support you in efficiently turning your innovative ideas into successful products.Over the past several years, the FDA’s 505(b)(2)regulatory pathway has enabled the approval of a variety of differentiated dosage forms for existing molecules
  • Translational Pharmaceutics - a Quotient Innovation

    Technical Data Translational Pharmaceutics - a Quotient Innovation

    Translational Pharmaceutics® accelerates drug development by integrating formulation development, real-time manufacturing and clinical testing. The platform is unique to Quotient Sciences and has been used over the last decade by global pharmaceutical and biotech companies across over 400 drug programs.
  • PBPK Modelling and Simulation at Quotient

    Technical Data PBPK Modelling and Simulation at Quotient

    Quotient is a leading expert in the application of physiologically based pharmacokinetic (PBPK) modelling and simulation (M&S) science to drug development. 

    Using GastroPlus™ we advise our clients on the potential in vivo performance of drugs and formulations to inform product and clinical development strategies. 


    Whether working in a consultancy relationship or as part of an integrated program of work, our PBPK expertise is underpinned by our unique and extensive experience in pharmaceutics, biopharmaceutics, DMPK and clinical research.
  • Pre-formulation & Material Sciences at Quotient

    Technical Data Pre-formulation & Material Sciences at Quotient

    Providing expertise to support pre-formulation development

    Our formulation development and material sciences experts have over 30 years’ experience in pre-formulation and solid state characterization.
  • Compounding and GMP Manufacturing for Product Supply at Quotient

    Technical Data Compounding and GMP Manufacturing for Product Supply at Quotient

    Quotient Sciences provides integrated pharmacy compounding, formulation, GMP manufacturing and clinical testing solutions to help clients achieve their proof-of-concept (POC) milestone quickly, saving them precious development time and money.  

    Begin your First-in-Human (FIH) Phase I testing with a fit-for-purpose, simple pharmacy preparation, and then seamlessly transition to a scalable, solid oral GMP drug product for Phase II trials, all within one organization.
  • Inhaled Product Development at Quotient

    Technical Data Inhaled Product Development at Quotient

    With more than 30 years’ experience, Quotient is a leader in the development, manufacture and assessment of inhalation products, helping clients to accelerate molecules from first-in-human through to proof-of-concept. 

    Our integrated capabilities and vast knowledge encompasses pre-formulation sciences, formulation development, device evaluation, clinical trial manufacturing and the clinical assessment of a variety of inhaled formats for nasal and pulmonary delivery.
  • High Potency Handling at Quotient

    Technical Data High Potency Handling at Quotient

    High Potency Drug Development & Manufacturing

    Highly potent active pharmaceutical ingredients (HPAPIs) are becoming increasingly common in drug development pipelines, especially in the oncology sector, as researchers search for therapies with greater selectivity and pharmacological activity. However, HPAPIs present additional CMC challenges due to the containment requirements to protect both the operators and manufacturing facilities. Their production processes may also require greater precision and control due to the very small quantities of drug present in the final dosage form.
  • Human ADME Studies at Quotient

    Technical Data Human ADME Studies at Quotient

    Whatever your requirements, Quotient Sciences can support you in the generation of clinical metabolism data for your drug development program and for NDA, MAA and global regulatory filings.
  • First-in-human to Proof-of-Concept at Quotient

    Technical Data First-in-human to Proof-of-Concept at Quotient

    Quotient Sciences’ Translational Pharmaceutics® approach enables First-in-Human studies by re-engineering the transition of your drug molecule into clinical development and shortening the timeline to Proof-of-Concept.

    How? Quotient’s Translational Pharmaceutics® platform integrates formulation development, real-time adaptive GMP manufacturing and clinical testing so that drug product manufacture occurs immediately prior to dosing.Each manufacture of drug product is therefore conducted in response to emerging clinical data. This approach delivers significant benefits to the development team.
  • Spray Drying at Quotient

    Technical Data Spray Drying at Quotient

    Overcoming poor drug solubility and bioavailability challenges

    Drug solubility has a significant impact on bioavailability. 70% of new chemical entities (NCEs) suffer from low aqueous solubility that can result in failure during clinical testing due to poor bioavailability. Selecting an appropriate drug formulation is imperative to the success of the program.
  • Project Management at Quotient

    Technical Data Project Management at Quotient

    Project Management at Quotient – A True Partnership
    Quotient is an innovative drug development and manufacturing partner supporting clients from candidate selection to commercial launch. With expertise in end-to-end Project Management and integrated project teams, we make drug development easier for our customers and dramatically reduce the time and cost of getting new medicines to patients.
  • John McDermott, Quotient Sciences, discusses the unique benefits of Translational Pharmaceutics

    Video John McDermott, Quotient Sciences, discusses the unique benefits of Translational Pharmaceutics

    John McDermott, Executive Director, Drug Development Solutions - Quotient Sciences discusses Translational Pharmaceutics at CPHI Worldwide, and how a recent Tufts study has proven the significant savings and financial benefits for drug developers who use Translational Pharmaceutics.
    2020-09-17
  • Formulation Strategies for Poorly Soluble Molecules at Quotient

    Technical Data Formulation Strategies for Poorly Soluble Molecules at Quotient

    As the number of poorly soluble compounds continues to increase in the industry development pipeline, conventional formulation strategies may not be sufficient to achieve acceptable levels of solubility in the gastrointestinal tract and hence absorption into the systemic circulation. Scientists will need to utilize advanced formulation technologies to maximize oral bioavailability.